返回 Agenda
Session Chair(s)
Yuhong WANG, MD
Drug Safety Lead
Shanghai Roche Pharmaceuticals Ltd, China
Speaker(s)
DILI Risk Assessment and Management in Clinical Development Program – Industry Perspective
Sean Zhao, MD, PHD
PV Quest, Inc., USA, China
Senior Pharmaceutical Consultant
Strengthening the Translational and Clinical Research on Drug-Induced Liver Injury (DILI) – Academic Perspective
Yimin MAO
RenJi Hospital, China
Professor
Huaqiong SHEN, MD, PHD
Jiangsu Hengrui Medicine Co., Ltd., China
Chief Medical Officer